Jennifer M. Specht

4.0k citations

106 papers · 2.4k indexed · h-index 27

Oncology top 2%
Radiology, Nuclear Medicine and Imaging top 2%
Molecular Biology
Cancer Research top 5%
Pulmonary and Respiratory Medicine top 5%

Co-authors: David A. Mankoff Julie R. Gralow Hannah M. Linden Brenda F. Kurland Erin K. Schubert Robert B. Livingston Georgiana K. Ellis Lanell M. Peterson
Topics: Medical Imaging Techniques and Applications (31 papers)Breast Cancer Treatment Studies (28 papers)HER2/EGFR in Cancer Research (22 papers)
Cited by: Oncology Cancer Research Radiology, Nuclear Medicine and Imaging
Journals: The Journal of Experimental Medicine Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States South Africa Czechia

In The Last Decade

Jennifer M. Specht

98 papers receiving 2.3k citations

Peers

Countries citing papers authored by Jennifer M. Specht

Since Specialization

Citations

This map shows the geographic impact of Jennifer M. Specht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer M. Specht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer M. Specht more than expected).

Fields of papers citing papers by Jennifer M. Specht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer M. Specht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer M. Specht. The network helps show where Jennifer M. Specht may publish in the future.

Co-authorship network of co-authors of Jennifer M. Specht

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer M. Specht. A scholar is included among the top collaborators of Jennifer M. Specht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer M. Specht. Jennifer M. Specht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A02 (HLA-A02) loss of heterozygosity (LOH). 2024 ·Journal of Clinical Oncology ·(unknown),Diane M. Simeone,Patrick Grierson,Kedar Kirtane,Maria Pia Morelli,Sandip Pravin Patel,Matthew L. Ulrickson,Saurabh Dahiya,Jong Chul Park,Jennifer M. Specht,Marwan Fakih,(unknown),Jessica Tebbets,John S. Welch,William Y. Go,David G. Maloney,Marcela V. Maus,(unknown),J. Randolph Hecht	0
2	Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trials 2024 ·EJNMMI Research ·Mark Muzi,Lanell M. Peterson,Jennifer M. Specht,Daniel S. Hippe,Alena Novakova-Jiresova,Jean H. Lee,Brenda F. Kurland,David A. Mankoff,Nancy A. Obuchowski,Hannah M. Linden,Paul E. Kinahan	0
3	Impact of Surveillance Mammography Intervals Less Than One Year on Performance Measures in Women With a Personal History of Breast Cancer 2023 ·Korean Journal of Radiology ·Janie M. Lee,Laura Ichikawa,Karen J. Wernli,Erin J. Aiello Bowles,Jennifer M. Specht,Karla Kerlikowske,Diana L. Miglioretti,Kathryn P. Lowry,Anna N.A. Tosteson,Natasha K. Stout,Nehmat Houssami,Tracy Onega,Diana S.M. Buist	0
4	204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients 2023 ·ESMO Open ·Hope S. Rugo,Robert Wesolowski,Erica Stringer-Reasor,Hyo S. Han,Jennifer M. Specht,(unknown),Peter Kabos,Ulka N. Vaishampayan,Seth A. Wander,Janice Lu,Keerthi Gogineni,Alexander I. Spira,Anne F. Schott,Maysa Abu‐Khalaf,Sarah C. Mutka,Samuel Suzuki,Igor Gorbatchevsky,Rachel M. Layman	1
5	Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status 2023 ·Cancer ·Kathryn P. Lowry,Laura Ichikawa,Rebecca A. Hubbard,Diana S.M. Buist,Erin J. Aiello Bowles,Louise M. Henderson,Karla Kerlikowske,Jennifer M. Specht,Brian L. Sprague,Karen J. Wernli,Janie M. Lee	6
6	Incidental discovery of second primary malignancies in patients diagnosed with breast cancer: An institutional case series. 2023 ·Journal of Clinical Oncology ·(unknown),(unknown),Shaveta Vinayak,William R. Gwin,Hannah M. Linden,Jennifer M. Specht,(unknown),Nancy E. Davidson,(unknown)	1
7	Abstract CT241: A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors 2023 ·Cancer Research ·Yara Abdou,E. Claire Dees,Joanne Mortimer,Naoto T. Ueno,Melissa M. Johnson,Richard T. Maziarz,Jennifer M. Specht,Yuan Yuan,(unknown),Mathew G. Angelos,Saar Gill,(unknown),Thomas Condamine,Daniel Cushing,Michael Klichinsky,Débora Barton,Ramona F. Swaby,Kim A. Reiss	2
8	Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy 2022 ·Cancer Causes & Control ·(unknown),Erin J. Aiello Bowles,Janie M. Lee,Jennifer M. Specht,Diana S.M. Buist	2
9	Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007–2016 2021 ·Radiology ·Janie M. Lee,Laura Ichikawa,Karen J. Wernli,Erin J. Aiello Bowles,Jennifer M. Specht,Karla Kerlikowske,Diana L. Miglioretti,Kathryn P. Lowry,Anna N.A. Tosteson,Natasha K. Stout,Nehmat Houssami,Tracy Onega,Diana S.M. Buist	20
10	Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis 2020 ·Breast Cancer Research and Treatment ·(unknown),Larissa Nekhlyudov,Janie M. Lee,Sara H. Javid,(unknown),Dianne Johnson,Timothy R. Gleason,Cary S. Kaufman,Jennifer M. Specht,(unknown),Karen J. Wernli	18
11	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib 2018 ·Clinical Breast Cancer ·(unknown),Hannah M. Linden,Vijayakrishna K. Gadi,Larissa A. Korde,Eve T. Rodler,Julie R. Gralow,Mary W. Redman,Kelsey K. Baker,Qian Wu,Isaac Jenkins,Brenda F. Kurland,Mitchell Garrison,Julie C. Smith,Jeanne E. Anderson,(unknown),Jennifer M. Specht	29
12	Test–Retest Reproducibility of ¹⁸F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network 2018 ·Journal of Nuclear Medicine ·Brenda F. Kurland,Lanell M. Peterson,Andrew Shields,Jean H. Lee,(unknown),Alena Novakova-Jiresova,Mark Muzi,Jennifer M. Specht,David A. Mankoff,Hannah M. Linden,Paul E. Kinahan	22
13	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer 2016 ·Clinical Cancer Research ·Eve T. Rodler,Brenda F. Kurland,Melissa Griffin,Julie R. Gralow,Peggy L. Porter,Rosa F. Yeh,Vijayakrishna K. Gadi,Jamie Guenthoer,Jan H. Beumer,Larissa A. Korde,Sandra Strychor,Brian F. Kiesel,Hannah M. Linden,John A. Thompson,Elizabeth M. Swisher,Xiaoyu Chai,Stacie Peacock Shepherd,Vincent L. Giranda,Jennifer M. Specht	69
14	First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies 2015 ·Clinical Cancer Research ·Pamela N. Münster,Rahul Aggarwal,David S. Hong,Jan H.M. Schellens,Ruud van der Noll,Jennifer M. Specht,Petronella O. Witteveen,Theresa L. Werner,Elizabeth Claire Dees,Emily K. Bergsland,Neeraj Agarwal,Joseph F. Kleha,M. Durante,Laurel M. Adams,Deborah A. Smith,Thomas A. Lampkin,Shannon R. Morris,Razelle Kurzrock	83
15	Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New 2015 ·Clinical Breast Cancer ·Eunpi Cho,(unknown),(unknown),Philip A. Stevenson,Ted Gooley,Georgiana K. Ellis,Jennifer M. Specht,Robert B. Livingston,Hannah M. Linden,Vijayakrishna K. Gadi	4
16	A Phase II Study of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688 2015 ·Journal of Nuclear Medicine ·Lale Kostakoğlu,Fenghai Duan,Michael O. Idowu,(unknown),Harry D. Bear,Mark Muzi,Jean Cormack,(unknown),Daniel A. Pryma,Jennifer M. Specht,Linda Hovanessian‐Larsen,(unknown),(unknown),Anthony F. Shields,David A. Mankoff	55
17	Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 2013 ·Clinical Cancer Research ·George Somlo,Francesco Atzori,Lewis C. Strauss,William J. Geese,Jennifer M. Specht,William J. Gradishar,(unknown),Oumar Sy,Linda T. Vahdat,Javier Cortés	36
18	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients 2012 ·EJNMMI Research ·Brenda F. Kurland,Vijayakrishna K. Gadi,Jennifer M. Specht,Kimberly H. Allison,Robert B. Livingston,Eve T. Rodler,Lanell M. Peterson,Erin K. Schubert,Xiaoyu Chai,David A. Mankoff,Hannah M. Linden	28
19	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer 2011 ·Clinical Cancer Research ·Hannah M. Linden,Brenda F. Kurland,Lanell M. Peterson,Erin K. Schubert,Julie R. Gralow,Jennifer M. Specht,Georgiana K. Ellis,Thomas J. Lawton,Robert B. Livingston,Philip H. Pétra,Jeanne M. Link,Kenneth A. Krohn,David A. Mankoff	107
20	Association between serial dynamic contrast‐enhanced MRI and dynamic ¹⁸F‐FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer 2010 ·Journal of Magnetic Resonance Imaging ·Savannah C. Partridge,(unknown),Robert K. Doot,Xiaoyu Chai,Brenda F. Kurland,Peter R. Eby,Jennifer M. Specht,Lisa K. Dunnwald,Erin K. Schubert,Constance D. Lehman,David A. Mankoff	34

About Jennifer M. Specht

Jennifer M. Specht is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 106 papers that have together received 2.4k indexed citations. Recurring topics across this work include Medical Imaging Techniques and Applications (31 papers), Breast Cancer Treatment Studies (28 papers) and HER2/EGFR in Cancer Research (22 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (534 citations) and Radiology, Nuclear Medicine and Imaging (766 citations). Jennifer M. Specht has collaborated with scholars based in United States, South Africa and Czechia. Frequent co-authors include David A. Mankoff, Julie R. Gralow, Hannah M. Linden, Brenda F. Kurland, Erin K. Schubert, Robert B. Livingston, Georgiana K. Ellis, Lanell M. Peterson, Lisa K. Dunnwald and Robert K. Doot. Their work appears in journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact